MedTrace Logo

Zanzalintinib in Unresectable and Progressive MPGGs

NCT07714551 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2026-07-20

No results posted yet for this study

Summary

This study is to examine the effects of oral daily zanzalintinib in participants with unresectable, progressive metastatic pheochromocytoma or paraganglioma.

Conditions

  • Pheochromocytoma
  • Paraganglioma

Interventions

DRUG

Zanzalintinib

Route: Oral Schedule: Daily

Sponsors & Collaborators

Principal Investigators

  • Kimbery Perez, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2027-01-09
Primary Completion
2031-01-01
Completion
2032-01-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07714551 on ClinicalTrials.gov